PT3366688T - Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase - Google Patents

Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Info

Publication number: PT3366688T
Authority: PT; Portugal
Prior art keywords: substituted pyrazolopyrimidines; glucocerebrosidase; activators; glucocerebrosidase activators; pyrazolopyrimidines
Prior art date: 2010-12-08

Application number

PT181650052T

Other languages

English (en)

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-08

Filing date

2011-12-08

Publication date

2022-05-11

2011-12-08 Application filed by Us Health filed Critical Us Health

2022-05-11 Publication of PT3366688T publication Critical patent/PT3366688T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT181650052T 2010-12-08 2011-12-08 Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase PT3366688T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42094610P	2010-12-08	2010-12-08

Publications (1)

Publication Number	Publication Date
PT3366688T true PT3366688T (pt)	2022-05-11

Family

ID=45498099

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT118107143T PT2649075T (pt)	2010-12-08	2011-12-08	Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase
PT181650052T PT3366688T (pt)	2010-12-08	2011-12-08	Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT118107143T PT2649075T (pt)	2010-12-08	2011-12-08	Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Country Status (24)

Country	Link
US (3)	US9353117B2 (pt)
EP (2)	EP2649075B1 (pt)
JP (1)	JP6154746B2 (pt)
KR (1)	KR101931224B1 (pt)
CN (1)	CN103534255B (pt)
AU (1)	AU2011338377B2 (pt)
BR (1)	BR112013014242B1 (pt)
CA (1)	CA2820362C (pt)
CY (1)	CY1125186T1 (pt)
DK (2)	DK3366688T3 (pt)
ES (2)	ES2912284T3 (pt)
HR (1)	HRP20220512T1 (pt)
HU (1)	HUE038635T2 (pt)
IL (2)	IL226767B (pt)
LT (1)	LT3366688T (pt)
MX (2)	MX385600B (pt)
PL (2)	PL2649075T3 (pt)
PT (2)	PT2649075T (pt)
RS (1)	RS63320B1 (pt)
RU (1)	RU2603637C2 (pt)
SI (2)	SI2649075T1 (pt)
TR (1)	TR201810523T4 (pt)
WO (1)	WO2012078855A1 (pt)
ZA (1)	ZA201304215B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2649075B1 (en)	2010-12-08	2018-04-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Substituted pyrazolopyrimidines as glucocerebrosidase activators
JP6061922B2 (ja) *	2011-06-22	2017-01-18	ザジェネラルホスピタルコーポレイション	プロテイノパチーの処置方法
EP2723746A1 (en)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
EA201490152A1 (ru)	2011-06-24	2014-05-30	Эмджен Инк.	Антагонисты trpm8 и их применение при лечении
JP2014517074A (ja)	2011-06-24	2014-07-17	アムジエン・インコーポレーテツド	Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
CA2852936A1 (en) *	2011-10-20	2013-04-25	Glaxosmithkline Llc	Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8952009B2 (en)	2012-08-06	2015-02-10	Amgen Inc.	Chroman derivatives as TRPM8 inhibitors
RS64234B1 (sr)	2012-12-07	2023-06-30	Vertex Pharma	Pirazolo[1,5-a]pirimidini korisni kao inhibitori atr kinaze za lečenje kancera
JP2016512816A (ja)	2013-03-15	2016-05-09	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な化合物
US8957078B2 (en)	2013-03-15	2015-02-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX389256B (es)	2013-10-04	2025-03-20	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
SI3077397T1 (sl)	2013-12-06	2020-02-28	Vertex Pharmaceuticals Inc.	2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati
WO2015143012A1 (en)	2014-03-19	2015-09-24	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
SG11201610197XA (en)	2014-06-05	2017-01-27	Vertex Pharma	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
NZ727399A (en)	2014-06-17	2022-07-29	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10118930B2 (en)	2014-11-03	2018-11-06	Bayer Pharma Aktiengesellschaft	Piperidinylpyrazolopyrimidinones and their use
HUE066864T2 (hu) *	2014-11-06	2024-09-28	Bial R&D Invest S A	Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében
ES2958391T3 (es)	2014-11-06	2024-02-08	Bial R&D Invest S A	Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
AU2015342883B2 (en) *	2014-11-06	2020-07-02	Bial - R&D Investments, S.A.	Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
EP3317282B1 (en) *	2015-07-01	2020-12-09	Northwestern University	Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
WO2017040877A1 (en) *	2015-09-04	2017-03-09	Lysosomal Therapeutics Inc.	Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
EP3344625A4 (en) *	2015-09-04	2019-03-27	Lysosomal Therapeutics Inc.	THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
EP4585268A3 (en)	2015-09-14	2025-10-15	Twelve Therapeutics, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
HK1258570A1 (zh)	2015-09-30	2019-11-15	Vertex Pharmaceuticals Inc.	使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
WO2017161137A1 (en) *	2016-03-16	2017-09-21	Lysosomal Therapeutics Inc.	Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
MX388912B (es) *	2016-04-06	2025-03-20	Lysosomal Therapeutics Inc	Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
SG11201808830YA (en) *	2016-04-06	2018-11-29	Lysosomal Therapeutics Inc	Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX2018012208A (es)	2016-04-06	2019-03-28	Lysosomal Therapeutics Inc	Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
BR112018072552A8 (pt) *	2016-05-05	2023-03-14	Lysosomal Therapeutics Inc	Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos
EP3452480A4 (en) *	2016-05-05	2019-11-06	Lysosomal Therapeutics Inc.	SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11345698B2 (en)	2016-05-05	2022-05-31	Bial—R&D Investments, S.A.	Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2018083085A1 (en) *	2016-11-02	2018-05-11	F. Hoffmann-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EP4438117A3 (en) *	2017-07-28	2024-12-18	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors and uses thereof
WO2019027765A1 (en)	2017-08-02	2019-02-07	Northwestern University	SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
MX2020003671A (es)	2017-10-06	2020-08-03	Forma Therapeutics Inc	Inhibicion de peptidasa especifica de ubiquitina 30.
JP7317721B2 (ja)	2018-01-31	2023-07-31	武田薬品工業株式会社	複素環化合物
IL278291B2 (en)	2018-05-17	2023-10-01	Forma Therapeutics Inc	Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US10882865B2 (en)	2018-08-31	2021-01-05	Northwestern University	Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
JP7179161B2 (ja)	2018-09-10	2022-11-28	イーライリリーアンドカンパニー	乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
PL3860989T3 (pl)	2018-10-05	2023-07-10	Forma Therapeutics, Inc.	Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
CA3115088A1 (en) *	2018-10-15	2020-04-23	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
AR117177A1 (es)	2018-12-10	2021-07-14	Lilly Co Eli	DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
MX2022002152A (es) *	2019-08-21	2022-05-18	Scripps Research Inst	Agonistas biciclicos del estimulador de genes de interferon sting.
AU2020349516A1 (en)	2019-09-17	2022-03-17	Bial-R&D Investments, S.A.	Substituted imidazole carboxamides and their use in the treatment of medical disorders
JP2022548747A (ja)	2019-09-17	2022-11-21	バイアル－アールアンドディーインベストメンツソシエダッドアノニマ	酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
JP2022549227A (ja)	2019-09-17	2022-11-24	バイアル－アールアンドディーインベストメンツソシエダッドアノニマ	医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物
EP4065546A1 (en) *	2019-11-25	2022-10-05	Gain Therapeutics SA	Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase
AR121251A1 (es)	2020-02-12	2022-05-04	Lilly Co Eli	Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004037373A2 (en)	2002-10-21	2004-05-06	The Scripps Research Institute	CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE
JP2004277337A (ja) *	2003-03-14	2004-10-07	Sumitomo Pharmaceut Co Ltd	ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2004089471A2 (en) *	2003-04-11	2004-10-21	Novo Nordisk A/S	NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
CA2545435C (en)	2003-11-12	2014-08-19	Amicus Therapeutics Inc.	Hydroxy piperidine derivatives to treat gaucher disease
CA2507348C (en) *	2004-05-13	2013-07-16	The Hospital For Sick Children	Real time methylumbelliferone-based assay
DE602005007215D1 (de) *	2004-05-14	2008-07-10	Cleveland Clinic Foundation	Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter
MXPA06014809A (es) *	2004-06-21	2007-02-12	Hoffmann La Roche	Derivados de pirazol-pirimidina.
DE102005007534A1 (de) *	2005-02-17	2006-08-31	Bayer Cropscience Ag	Pyrazolopyrimidine
KR20080087070A (ko)	2005-05-20	2008-09-30	알란토스 파마슈티컬즈 홀딩, 인코포레이티드	피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
US20070155737A1 (en)	2005-05-20	2007-07-05	Alantos Pharmaceuticals, Inc.	Heterobicyclic metalloprotease inhibitors
WO2007008541A2 (en)	2005-07-08	2007-01-18	Kalypsys, Inc.	Cellular cholesterol absorption modifiers
BRPI0614577A2 (pt) *	2005-08-15	2011-04-05	Hoffmann La Roche	derivados de piperidina e piperazina como antagonistas de p2x3
WO2007046548A1 (en) *	2005-10-21	2007-04-26	Mitsubishi Tanabe Pharma Corporation	Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
WO2007048066A2 (en) *	2005-10-21	2007-04-26	Exelixis, Inc.	Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2008054947A2 (en)	2006-10-02	2008-05-08	The Brigham And Women's Hospital, Inc.	Structure of acid beta-glucosidase and methods for identifying therapeutic agents
WO2008045664A2 (en)	2006-10-06	2008-04-17	Kalypsys, Inc.	Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008063671A2 (en)	2006-11-20	2008-05-29	Alantos Pharmaceuticals Holding, Inc.	Heterobicyclic metalloprotease inhibitors
CA2683713A1 (en)	2007-04-13	2008-10-23	Amicus Therapeutics, Inc.	Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
WO2008134035A1 (en)	2007-04-27	2008-11-06	Panacos Pharmaceuticals, Inc.	Alpha-unsubstituted arylmethyl piperazine pyrazolo[1,5-a] pyrimidine amide derivatives
EP3000320B1 (en)	2007-05-16	2019-01-16	The Brigham and Women's Hospital, Inc.	Treatment of synucleinopathies
WO2008154207A1 (en)	2007-06-08	2008-12-18	The Burnham Institute For Medical Research	Methods and compounds for regulating apoptosis
JP5337405B2 (ja)	2007-09-17	2013-11-06	ザ・ホスピタル・フォー・シック・チルドレン	ゴーシェ病の治療方法
WO2009049421A1 (en)	2007-10-18	2009-04-23	The Hospital For Sick Children	Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
EP2219646A4 (en) *	2007-12-21	2010-12-22	Univ Rochester	PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
CA2727389A1 (en) *	2008-06-10	2009-12-17	Prabha N. Ibrahim	5h-pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2010003023A2 (en)	2008-07-01	2010-01-07	Zacharon Pharmaceuticals, Inc.	Heparan sulfate inhibitors
WO2010086040A1 (en) *	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
EP2649075B1 (en)	2010-12-08	2018-04-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Substituted pyrazolopyrimidines as glucocerebrosidase activators
HUE066864T2 (hu) *	2014-11-06	2024-09-28	Bial R&D Invest S A	Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében

2011
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 MX MX2018000385A patent/MX385600B/es unknown
- 2011-12-08 ES ES18165005T patent/ES2912284T3/es active Active
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/da active
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/ja active Active
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/hu unknown
- 2011-12-08 SI SI201131532T patent/SI2649075T1/sl unknown
- 2011-12-08 PT PT118107143T patent/PT2649075T/pt unknown
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/hr unknown
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/lt unknown
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/tr unknown
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/ko active Active
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/zh active Active
- 2011-12-08 MX MX2013006462A patent/MX354506B/es active IP Right Grant
- 2011-12-08 RS RS20220422A patent/RS63320B1/sr unknown
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/pt active IP Right Grant
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 PL PL11810714T patent/PL2649075T3/pl unknown
- 2011-12-08 PL PL18165005T patent/PL3366688T3/pl unknown
- 2011-12-08 SI SI201132052T patent/SI3366688T1/sl unknown
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/ru active
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/es active Active
- 2011-12-08 PT PT181650052T patent/PT3366688T/pt unknown
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/el unknown

Also Published As

Publication number	Publication date
HRP20220512T1 (hr)	2022-05-27
JP2013544893A (ja)	2013-12-19
US20160346284A1 (en)	2016-12-01
CY1125186T1 (el)	2024-12-13
DK2649075T3 (en)	2018-07-30
RS63320B1 (sr)	2022-07-29
KR101931224B1 (ko)	2018-12-20
AU2011338377A1 (en)	2013-07-04
MX2013006462A (es)	2013-10-01
US10925874B2 (en)	2021-02-23
CN103534255A (zh)	2014-01-22
PL2649075T3 (pl)	2018-09-28
US9974789B2 (en)	2018-05-22
HUE038635T2 (hu)	2018-11-28
KR20140010012A (ko)	2014-01-23
LT3366688T (lt)	2022-05-25
AU2011338377B2 (en)	2016-08-04
EP3366688A1 (en)	2018-08-29
US20140249145A1 (en)	2014-09-04
US20180263988A1 (en)	2018-09-20
DK3366688T3 (da)	2022-05-02
AU2011338377A8 (en)	2015-10-29
CA2820362A1 (en)	2012-06-14
ZA201304215B (en)	2014-03-26
TR201810523T4 (tr)	2018-08-27
PL3366688T3 (pl)	2022-05-23
ES2912284T3 (es)	2022-05-25
IL226767B (en)	2018-06-28
CN103534255B (zh)	2016-12-21
EP2649075B1 (en)	2018-04-25
SI2649075T1 (sl)	2018-10-30
WO2012078855A1 (en)	2012-06-14
RU2013126094A (ru)	2015-01-20
MX354506B (es)	2018-01-16
MX385600B (es)	2025-03-18
EP3366688B1 (en)	2022-02-09
JP6154746B2 (ja)	2017-06-28
BR112013014242A2 (pt)	2018-06-26
EP2649075A1 (en)	2013-10-16
CA2820362C (en)	2020-03-24
SI3366688T1 (sl)	2022-07-29
ES2681218T3 (es)	2018-09-12
IL259648A (en)	2018-07-31
RU2603637C2 (ru)	2016-11-27
PT2649075T (pt)	2018-07-30
BR112013014242B1 (pt)	2022-02-22
IL259648B (en)	2021-03-25
US9353117B2 (en)	2016-05-31

Publication	Publication Date	Title
IL259648A (en)	2018-07-31	Pyrazolopyrimidines are converted as glucoserbrosidase activators
AP3607A (en)	2016-02-26	Substituted imidazopyridazines
IL222646A0 (en)	2012-12-31	N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
PL2534132T3 (pl)	2017-09-29	Podstawione pirolidyno-2-karboksyamidy
ZA201209117B (en)	2013-09-25	Tetrahydro-pyrido-pyrimidine derivatives
EP2534256A4 (en)	2013-07-24	NEW USES
IL226192A (en)	2016-06-30	Sodium –1 h– pyrazole – 5 – olate is converted
EP2541164A4 (en)	2016-09-07	COOLER
GB2490849B (en)	2020-01-01	Di-aspirin derivatives
IL225312A0 (en)	2013-06-27	New combinations
HU1000243D0 (en)	2010-06-28	8-hidroxy-quinoline derivatives
AU4538P (en)	2013-05-16	H22 Grevillea juniperina
AU332681S (en)	2010-09-08	Spindle
GB201008355D0 (en)	2010-07-07	Solid supports
ZA201209248B (en)	2013-08-28	Amido-tropane derivatives
IL220983A0 (en)	2012-09-24	2-aldoximino-5-fluoropyrimidine derivatives
GB201019442D0 (en)	2010-12-29	Novel combinations
AU2010900285A0 (en)	2010-02-11	Sparger